Navrogen
Philadelphia, US · Founded 2017 · Delaware corporation
Navrogen is a biopharmaceutical company developing therapeutic agents that counter tumor-produced Humoral Immuno-Oncology (HIO) factors linked to suppressed humoral immunity and poor response to immune-mediated anti-cancer therapies. It uses proprietary screening, antibody engineering technologies, and diagnostic assays to identify patients whose tumors produce HIO factors, targeting cancer and immune-related disorders.
Founders & leadership
Navrogen was founded in 2017 by Nicholas Nicolaides and Luigi Grasso.
NN
Nicholas NicolaidesCo-founder, President & CEO
LG
Luigi GrassoCo-founder, SR VP & Chief Scientific Officer
SK
Steven KyriakosVP of Finance and Operations
Reported raises · per SEC filings
Form D private placements$12.8M disclosed across 3 rounds · 2018–2024
▶$542KraisedJun 2024 · 13 investors · BiotechnologyRule 506(b)
▶$542KraisedJun 2024 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Allan BedwickDirector
- Luigi GrassoExecutive Officer, Director
- Nicholas C. NicolaidesExecutive Officer, Director
- Leon O Moulder, JrDirector
- Offering amount
- $1M
- Amount sold
- $542K
- Minimum investment
- $5K
- Proceeds to insiders
- $542K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.1MraisedFeb 2023 · 20 investors · BiotechnologyRule 506(b)
▶$9.1MraisedFeb 2023 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas C. NicolaidesExecutive Officer, Director
- Leon O. Moulder, Jr.Director
- Allan BedwickDirector
- Luigi GrassoExecutive Officer, Director
- Offering amount
- $9.3M
- Amount sold
- $9.1M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.2MraisedSep 2019 · 18 investors · BiotechnologyRule 506(b)
▶$3.2MraisedSep 2019 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas NicolaidesExecutive Officer, Director
- Luigi GrassoExecutive Officer, Director
- Steven G KyriakosExecutive Officer
- Offering amount
- $3.2M
- Amount sold
- $3.2M
- Placement agents
- NA
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Nephrogen7 shared keywordsNephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Urogen5 shared keywordsUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
Geron5 shared keywordsGeron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.
Anthrogen4 shared keywordsAnthrogen develops Odyssey, a family of protein language models with 102 billion parameters designed for multi-objective protein design. The models provide an API for researchers and organizations in biotechnology and drug discovery.
Companies competing with Navrogen for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Navrogen do?
- Navrogen is a biopharmaceutical company developing therapeutic agents that counter tumor-produced Humoral Immuno-Oncology (HIO) factors linked to suppressed humoral immunity and poor response to immune-mediated anti-cancer therapies. It uses proprietary screening, antibody engineering technologies, and diagnostic assays to identify patients whose tumors produce HIO factors, targeting cancer and immune-related disorders.
- Who founded Navrogen?
- Navrogen was founded by Nicholas Nicolaides, Luigi Grasso in 2017.
- How much funding has Navrogen raised?
- Navrogen has disclosed $12.8M raised across 3 rounds.
- Where is Navrogen headquartered?
- Navrogen is headquartered in Philadelphia, US.